- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Patent holdings for IPC class A61K 31/5025
Total number of patents in this class: 2017
10-year publication summary
131
|
119
|
145
|
153
|
146
|
202
|
187
|
180
|
191
|
44
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 5080 |
60 |
Janssen Pharmaceutica N.V. | 3839 |
38 |
Novartis AG | 11238 |
36 |
Takeda Pharmaceutical Company Limited | 2961 |
36 |
F. Hoffmann-La Roche AG | 7958 |
34 |
Genentech, Inc. | 3742 |
28 |
Boehringer Ingelheim International GmbH | 4629 |
27 |
Gilead Sciences, Inc. | 1879 |
27 |
AstraZeneca AB | 3042 |
24 |
Agios Pharmaceuticals, Inc | 200 |
20 |
Vanderbilt University | 1731 |
20 |
Pfizer Inc. | 3322 |
19 |
Nihon Nohyaku Co., Ltd. | 313 |
19 |
Bayer Pharma AG | 1096 |
16 |
Amgen Inc. | 3779 |
16 |
Incyte Corporation | 918 |
16 |
Merck Sharp & Dohme LLC | 3689 |
16 |
Merck Patent GmbH | 5909 |
15 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
14 |
Daiichi Sankyo Company, Limited | 1829 |
13 |
Other owners | 1523 |